TY - JOUR
T1 - Thrombotic microangiopathy in children
AU - Palma, Lilian Monteiro P.
AU - Vaisbich-Guimarães, Maria Helena
AU - Sridharan, Meera
AU - Tran, Cheryl L.
AU - Sethi, Sanjeev
N1 - Funding Information:
SS would like to thank the Division of Anatomic Pathology, Innovation fund, Mayo Clinic.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to International Pediatric Nephrology Association.
PY - 2022/9
Y1 - 2022/9
N2 - The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ involvement. It comprises a spectrum of underlying etiologies that may differ in children and adults. In children, apart from ruling out shigatoxin-associated hemolytic uremic syndrome (HUS) and other infection-associated TMA like Streptococcus pneumoniae-HUS, rare inherited causes including complement-associated HUS, cobalamin defects, and mutations in diacylglycerol kinase epsilon gene must be investigated. TMA should also be considered in the setting of solid organ or hematopoietic stem cell transplantation. In this review, acquired and inherited causes of TMA are described with a focus on particularities of the main causes of TMA in children. A pragmatic approach that may help the clinician tailor evaluation and management is provided. The described approach will allow for early initiation of treatment while waiting for the definitive diagnosis of the underlying TMA.
AB - The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ involvement. It comprises a spectrum of underlying etiologies that may differ in children and adults. In children, apart from ruling out shigatoxin-associated hemolytic uremic syndrome (HUS) and other infection-associated TMA like Streptococcus pneumoniae-HUS, rare inherited causes including complement-associated HUS, cobalamin defects, and mutations in diacylglycerol kinase epsilon gene must be investigated. TMA should also be considered in the setting of solid organ or hematopoietic stem cell transplantation. In this review, acquired and inherited causes of TMA are described with a focus on particularities of the main causes of TMA in children. A pragmatic approach that may help the clinician tailor evaluation and management is provided. The described approach will allow for early initiation of treatment while waiting for the definitive diagnosis of the underlying TMA.
KW - Complement
KW - DGKe
KW - Hemolytic uremic syndrome
KW - Hypertension
KW - Infection
KW - Thrombotic microangiopathy
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=85123082900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123082900&partnerID=8YFLogxK
U2 - 10.1007/s00467-021-05370-8
DO - 10.1007/s00467-021-05370-8
M3 - Review article
C2 - 35041041
AN - SCOPUS:85123082900
SN - 0931-041X
VL - 37
SP - 1967
EP - 1980
JO - Pediatric nephrology (Berlin, Germany)
JF - Pediatric nephrology (Berlin, Germany)
IS - 9
ER -